MC‐T‐DOX is activated by MT1‐MMP on tumor endothelial cells to release cilengitide, which then improves tumor blood perfusion, thereby enhancing intratumoral delivery of MC‐T‐DOX. Here, MMP14 is linked to neoplasm.